Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AKT1 | P31749 | 1/20 | 0.37 |
| ▸ | BCHE | P06276 | 1/20 | 0.37 |
| ▸ | MALT1 | Q9UDY8 | 1/20 | 0.36 |
| ▸ | IDO1 | P14902 | 1/20 | 0.36 |
| ▸ | GPR88 | Q9GZN0 | 1/20 | 0.35 |
| ▸ | CTSS | P25774 | 2/20 | 0.34 |
| ▸ | CTSK | P43235 | 1/20 | 0.34 |
| ▸ | NTRK1 | P04629 | 2/20 | 0.34 |
| ▸ | CKS1B | P61024 | 1/20 | 0.34 |
| ▸ | SKP1 | P63208 | 1/20 | 0.34 |
| ▸ | SKP2 | Q13309 | 1/20 | 0.34 |
| ▸ | DRD2 | P14416 | 1/20 | 0.34 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.34 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.33 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.33 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5492718 | 0.91 | BCHE (0.40) | BCHEMALT1IDO1NTRK1CKS1B | |
| SCHEMBL6427256 | 0.85 | BCHE (0.35) | AKT1BCHEMALT1IDO1CKS1B | |
| SCHEMBL3121409 | 0.84 | CTSS (0.37) | AKT1CTSSCTSKCKS1BSKP1 | |
| SCHEMBL20262161 | 0.84 | LPAR1 (0.37) | AKT1CTSSCTSKMAPK1SCN9A | |
| SCHEMBL5500423 | 0.83 | IDO1 (0.44) | BCHEMALT1IDO1CKS1BSKP1 | |
| SCHEMBL27620815 | 0.83 | CYP3A4 (0.44) | DRD2SIGMAR1CYP3A4 | |
| SCHEMBL27661812 | 0.83 | SIGMAR1 (0.39) | BCHEIDO1CKS1BSKP1SKP2 | |
| SCHEMBL5496197 | 0.82 | SIGMAR1 (0.38) | BCHECKS1BSKP1SKP2SIGMAR1 | |
| SCHEMBL27641150 | 0.82 | BCHE (0.36) | BCHEIDO1CKS1BSKP1SKP2 | |
| SCHEMBL3113414 | 0.81 | AKT1 (0.35) | AKT1CTSSCTSKCKS1BSKP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1663245-B1 | CEPHEM COMPOUNDS | ASTELLAS PHARMA INC (JP) | 2010-04-07 | — | — | EP | disclosed |
| US-7192943-B2 | Cephem compounds | ASTELLAS PHARMA INC. (JP) | 2007-03-20 | — | — | US | disclosed |
| US-20050096306-A1 | Cephem compounds | FUJISAWA PHARMACEUTICAL CO. LTD. (JP) | 2005-05-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050096306-A1 | Cephem compounds | CEP170, ASS1, C1S | AKT1 1575/4885BCHE 489/4885MALT1 4839/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.